Kenneth R. Shroyer, MD, PhD

Kenneth R. Shroyer, MD, PhD      
The Marvin Kuschner Professor
Chair of Pathology
Basic Science Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691  

Tel:  (631) 444-3000
Fax:  (631) 444-3424
email:   kenneth.shroyer@stonybrookmedicine.edu
 
Research Summary:   
Dr. Shroyer completed his graduate training in Experimental Pathology under the supervision of Dr. Paul K. Nakane, the inventor of the immunoperoxidase method. Dr. Shroyer has maintained continuous federally-funded grant support since 1993. He invented the method of DNP labeling of nucleic acid probes, was a pioneer in the development of methods for in situ hybridization of mRNAS in the early 1980s, and was the first to report the analysis of x-chromosome inactivation in archival tissues as a marker of clonality. He participated in the early validation of tyramide-based signal amplification technology for in situ hybridization and high sensitivity immunohistochemistry. He has also been engaged in the development of novel approaches for antibody labeling using nanoparticles for both in vivo imaging and for immunohistochemical applications in collaboration with scientists in biomedical engineering for over six years. He is also highly experienced in the development and application of methods for multiplexed immunofluorescence and multiplexed enzyme-based immunohistochemical protocols.
 
Clinical Practice:
Dr. Shroyer is Board Certified in Anatomic and Clinical Pathology (1991), with subspecialty certification in Cytopathology (1995).  He is a general surgical pathologist with a subspecialty expertise in gynecologic oncology.  He also has extensive experience in gynecologic and non-gynecologic cytopathology, including fine needle aspiration cytopathology. He has pioneered novel methods to improve the accuracy of the cytologic and histologic classification of tumors.  

Peer Reviewed Publications: 

 
*including IMAT, Applied Emerging Technologies for Cancer Res., Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, SPOREs in Breast, Cervical, Endometrial, Ovarian, Skin Cancers, Lymphoma, Genitourinary, and Gastrointestinal Cancers and In Vivo Cellular and Molecular Imaging Centers (ICMICs), Cancer Target Discovery and Develop. (CTDD) Network